JP2023534916A5 - - Google Patents
Info
- Publication number
- JP2023534916A5 JP2023534916A5 JP2022581408A JP2022581408A JP2023534916A5 JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5 JP 2022581408 A JP2022581408 A JP 2022581408A JP 2022581408 A JP2022581408 A JP 2022581408A JP 2023534916 A5 JP2023534916 A5 JP 2023534916A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- subject
- administration
- nmosd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046133P | 2020-06-30 | 2020-06-30 | |
| US63/046,133 | 2020-06-30 | ||
| US202063052093P | 2020-07-15 | 2020-07-15 | |
| US63/052,093 | 2020-07-15 | ||
| US202063071092P | 2020-08-27 | 2020-08-27 | |
| US63/071,092 | 2020-08-27 | ||
| PCT/US2021/039911 WO2022006283A2 (en) | 2020-06-30 | 2021-06-30 | Methods of treating neuromyelitis optica spectrum disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534916A JP2023534916A (ja) | 2023-08-15 |
| JP2023534916A5 true JP2023534916A5 (https=) | 2024-07-09 |
Family
ID=79321915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581408A Pending JP2023534916A (ja) | 2020-06-30 | 2021-06-30 | 視神経脊髄炎スペクトラム障害を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230406928A1 (https=) |
| EP (1) | EP4172211A4 (https=) |
| JP (1) | JP2023534916A (https=) |
| KR (1) | KR20230030642A (https=) |
| CN (1) | CN116234571A (https=) |
| AU (1) | AU2021299307A1 (https=) |
| BR (1) | BR112022026747A2 (https=) |
| CA (1) | CA3178954A1 (https=) |
| IL (1) | IL299381A (https=) |
| MX (1) | MX2022016236A (https=) |
| WO (1) | WO2022006283A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021368769A1 (en) * | 2020-10-29 | 2023-06-08 | Viela Bio, Inc. | Use of an anti-cd19 antibody to treat autoimmune disease |
| CN117797245A (zh) * | 2023-12-29 | 2024-04-02 | 广州赛莱拉干细胞科技股份有限公司 | 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020263418A1 (en) * | 2019-04-24 | 2021-11-11 | Viela Bio, Inc. | Use of an anti-CD19 antibody to treat autoimmune disease |
| AU2021368769A1 (en) * | 2020-10-29 | 2023-06-08 | Viela Bio, Inc. | Use of an anti-cd19 antibody to treat autoimmune disease |
-
2021
- 2021-06-30 WO PCT/US2021/039911 patent/WO2022006283A2/en not_active Ceased
- 2021-06-30 JP JP2022581408A patent/JP2023534916A/ja active Pending
- 2021-06-30 CA CA3178954A patent/CA3178954A1/en active Pending
- 2021-06-30 EP EP21834411.7A patent/EP4172211A4/en active Pending
- 2021-06-30 MX MX2022016236A patent/MX2022016236A/es unknown
- 2021-06-30 BR BR112022026747A patent/BR112022026747A2/pt unknown
- 2021-06-30 IL IL299381A patent/IL299381A/en unknown
- 2021-06-30 CN CN202180046409.5A patent/CN116234571A/zh active Pending
- 2021-06-30 AU AU2021299307A patent/AU2021299307A1/en active Pending
- 2021-06-30 KR KR1020237002980A patent/KR20230030642A/ko active Pending
-
2022
- 2022-12-28 US US18/147,287 patent/US20230406928A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Collongues et al. | Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options | |
| JP7125932B2 (ja) | 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法 | |
| Yang et al. | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder | |
| US9458241B2 (en) | Antibody induced cell membrane wounding | |
| Tang et al. | Long-term study of mycophenolate mofetil treatment in IgA nephropathy | |
| EP3747464B1 (en) | Methods for treating progressive multiple sclerosis using an anti-cd20 antibody | |
| US20220002402A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| JP7541505B2 (ja) | アルツハイマー病の治療及び予防方法 | |
| JP2022033868A5 (https=) | ||
| HUE025759T2 (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody | |
| JP2024112859A5 (https=) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2018523684A5 (https=) | ||
| JP2021532126A5 (https=) | ||
| JP2023534916A5 (https=) | ||
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| EP2849783A1 (en) | Combination of cd37 antibodies with further agents | |
| JP2019512472A5 (https=) | ||
| WO2018015880A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2025514142A5 (https=) | ||
| US20070081989A1 (en) | Treatment of B cell diseases using anti-germline antibody binding agents | |
| JP2020500161A5 (https=) | ||
| JP2023510854A5 (https=) | ||
| JP2021529766A5 (https=) | ||
| JP2024532438A5 (https=) |